Contineum Therapeutics (CTNM) Free Cash Flow (2023 - 2026)

Contineum Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$16.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 14.66% year-over-year to -$16.6 million; the TTM figure through Mar 2026 stood at -$57.4 million (down 44.68% YoY), while the FY2025 annual figure was -$55.3 million, down 65.81% from the prior year.
• Free Cash Flow was -$16.6 million for Q1 2026 at Contineum Therapeutics, down from -$12.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $40.6 million in Q2 2023 to a low of -$16.6 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$6.6 million across 4 years, with a median of -$10.4 million in 2024.
• Biggest YoY gain for Free Cash Flow was 2.46% in 2024; the steepest drop was 121.2% in 2024.
• A 4-year view of Free Cash Flow shows it stood at -$10.6 million in 2023, then rose by 2.46% to -$10.4 million in 2024, then fell by 23.97% to -$12.9 million in 2025, then dropped by 28.98% to -$16.6 million in 2026.
• The last three Free Cash Flow figures came in at -$16.6 million (Q1 2026), -$12.9 million (Q4 2025), and -$12.3 million (Q3 2025), per Business Quant data.